Bulevirtide HDV Therapy: Promising Results in D...

Bulevirtide HDV therapy has shown remarkable promise in Gilead's final results from the Phase 3 MYR301 study. The findings indicate that longer bulevirtide monotherapy for chronic hepatitis delta virus (HDV) leads to sustained virologic suppressio...